Betesil® completes Mutual Recognition Procedure
(09.10.2006)
IBSA successfully finalised the Mutual Recognition Procedure of Betesil®, an innovative 0.1% betamethasone valerate medicated plaster
|
| |
Read more
|
|
|
|
|
|
|
 |
Chondrosulf confirmed as structure modifying drug for osteoarthritis
(23.06.2006)
The first results from a huge study investigating the clinical activity of Chondrosulf (chondroitin 4&6 sulfate) in the long term management of osteoarthtritis have been presented at the annual meeting of the European League Against Reumathism (EULAR) held in Amsterdam on June 21-24 2006.
|
| |
Read more
|
|
|
|
|
|
|
|
Fostimon® completes Mutual Recognition Procedure
(19.01.2006)
IBSA has successfully concluded the Mutual Recognition Procedure of Fostimon, human-derived FSH for ovulation induction and controlled ovarian hyperstimulation.
|
| |
Read more
|
|
|
|
|
|
|
|
IBSA among finalists for the Italian-Switzerland Company Award
(14.01.2006)
IBSA has been awarded among the 6 final companies at the first edition of the Italian-Switzerland Company Award which took place in Lugano last 19th January, 2006.
|
| |
Read more
|
|
|
|
|
|
|
|
Betesil® completes Mutual Recognition Procedure
(12.12.2005)
IBSA successfully finalised the Mutual Recognition Procedure of Betesil®, an innovative 0.1% betamethasone valerate medicated plaster.
|
| |
Read more
|
|
|
|
|
|
|
|
